Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 157-163

  Dingemanse, Jasper ^a   Van Giersbergen, Paul L M ^a   Patat, Alain ^b   Nilsson, Per N ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Biotrial   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BOSENTAN; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; GEOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; MALE; PYRIMIDINONES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 77950683118     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1506     Document Type: Article

References (26)

1. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-1030.
2. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J Med 2006; 73:1037-1044.
3. 3. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170:1212-1217. (Pubitemid 39577380)
4. 4. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739. (Pubitemid 23170122)
5. 5. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120:1562-1569. (Pubitemid 33078473)
6. 6. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin W Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928. (Pubitemid 46981654)
7. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25:2243-2278.
8. 8. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92:1164-1166. (Pubitemid 44125252)
9. Degano B, Yaici A, Le PT, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33:92-98.
10. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS 2008; 22 Suppl 3:S55-S62.
11. 11. Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43:1089-1115. (Pubitemid 40013178)
12. 12. van Giersbergen PLM, Halabi A, Dingemanse J. Singleand multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53:589-595. (Pubitemid 34621784)
13. 13. van Giersbergen PLM, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 2007; 81:414-419. (Pubitemid 46364484)
14. 14. van Giersbergen PLM, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71:253-262. (Pubitemid 34311454)
15. 15. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008; 48:610-618. (Pubitemid 351503516)
16. 16. Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATPlBl and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35:1400-1407. (Pubitemid 47121782)
17. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steadystate bosentan and sildenafil. Eur J Clin Pharmacol 2008; 64:43-50.
18. 18. Binet I, Wallnöfer A, Weber C, Jones R, Thiel P. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporin A. Kidney Int 2000; 57:224-231. (Pubitemid 30227769)
19. 19. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53:4-9. (Pubitemid 38072176)
20. 20. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007; 60:1195-1205. (Pubitemid 350176278)
21. 21. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802. (Pubitemid 36432083)
22. 22. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853-1859. (Pubitemid 47481578)
23. 23. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34:1229-1236. (Pubitemid 43920883)
24. 24. Ehrhardt M, Möck M, Haefeli WE, Mikus G, Burhenne J. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850:249-258. (Pubitemid 46629170)
25. 25. Dell D, Lausecker B, Hopfgartner G, van Giersbergen PLM, Dingemanse J. Evolving bioanalytical methods for the cardiovascular drug bosentan. Chromatographia 2002; 55 Suppl 1:S115-S119. (Pubitemid 34548120)
26. 26. Crommentuyn KML, Mulder JW, Mairuhu ATA, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther 2004; 9:779-785. (Pubitemid 39434342)